Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Kassassir 2016 Chem Biol Interact

From Bioblast
Publications in the MiPMap
Kassassir H, Siewiera K, Talar M, Stec-Martyna E, Pawlowska Z, Watala C (2016) Non-enzymatic modifications of prostaglandin H synthase 1 affect bifunctional enzyme activity - Implications for the sensitivity of blood platelets to acetylsalicylic acid. Chem Biol Interact 253:78-92.

» PMID: 27083140

Kassassir H, Siewiera K, Talar M, Stec-Martyna E, Pawlowska Z, Watala C (2016) Chem Biol Interact

Abstract: Due to its ability to inhibit the blood platelet PGHS-1, acetylsalicylic acid (ASA, Aspirin(®)) is widely used as a preventive agent in atherothrombotic diseases. However, its beneficial effects seem to be lower in diabetic patients, suggesting that protein glycation may impair effective ASA-mediated acetylation process. On the other hand, it is proposed that ASA can prevent some of the late complications of diabetes by lowering the extent of glycation at protein free amino groups. The aim of this work was to evaluate the extents of non-enzymatic N-glycosylation (glycation) and acetylation of blood platelet PGHS-1 (COX-1) and the competition between glycation and acetylation was investigated in order to demonstrate how these two reactions may compete against platelet PGHS-1. When PGHS-1 was incubated with glycating/acetylating agents (glucose, Glu; 1,6-bisphosphofructose, 1,6-BPF; methylglyoxal, MGO, acetylsalicylic acid, ASA), the enzyme was modified in 13.4 ± 1.6, 5.3 ± 0.5, 10.7 ± 1.2 and 6.4 ± 1.1 mol/mol protein, respectively, and its activity was significantly reduced. The prior glycation/carbonylation of PGHS-1 with Glu, 1,6-BPF or MGO decreased the extent of acetylation from 6.4 ± 1.1 down to 2.5 ± 0.2, 3.6 ± 0.3 and 5.2 ± 0.2 mol/mol protein, respectively, but the enzyme still remained susceptible to the subsequent inhibition of its activity with ASA. When PGHS-1 was first acetylated with ASA and then incubated with glycating/carbonylating agents, we observed the following reductions in the enzyme modifications: from 13.4 ± 1.6 to 8.7 ± 0.6 mol/mol protein for Glu, from 5.3 ± 0.5 to 3.9 ± 0.3 mol/mol protein for 1,6-BPF and from 10.7 ± 1.2 to 7.5 ± 0.5 mol/mol protein for MGO, however subsequent glycation/carbonylation did not significantly affect PGHS-1 function. Overall, our outcomes allow to better understand the structural aspects of the chemical competition between glycation and acetylation of PGHS-1.

Copyright © 2016 Elsevier Ireland Ltd. All rights reserved. Keywords: Acetylation, Acetylsalicylic acid, Diabetes mellitus, Glycation, Non-enzymatic modifications, PGHS-1 activity, PBMC

O2k-Network Lab: PL Lodz Watala C

Labels: MiParea: Respiration, Pharmacology;toxicology  Pathology: Diabetes 

Organism: Other mammals 

Preparation: Enzyme 

HRR: Oxygraph-2k 

2016-10, Aspirin